A Comprehensive Overview Reveals Ketamine Therapy As A Successful Treatment Option For Anxiety, PTSD, And Depression

Santa Barbara, CA (Newsworthy.ai) Monday Apr 24, 2023 @ 8:00 PM Central —

According to medical studies, patients who use ketamine have experienced long-lasting relief from symptoms such as low mood and suicidal thoughts within hours to days. The therapy has shown excellent short-term success rates, with research indicating that longer-term outcomes are often achieved, resulting in more meaningful improvements in functioning and quality of life.

As a result, ketamine has become a popular choice for individuals struggling with anxiety, PTSD, and depression. The treatment works by activating the brain's glutamate system, leading to increased brain-derived neurotrophic factor (BDNF) signaling, resulting in new synaptic connections and improved mood and cognitive function.

The medical community has seen great success with its patients using ketamine therapy. Doctors have seen the positive impact ketamine can have on individuals struggling with mental health conditions. Patients need to understand that treatment with ketamine is a viable option for those who may have exhausted other options.

Ketamine is considered a safe and effective treatment with a low potential for addiction or abuse. Patients can receive treatment via intravenous infusion or nasal spray.

Individuals struggling with anxiety, PTSD, and depression should consider ketamine therapy a viable option. The treatment's effectiveness, safety, and long-term success rates are well-supported by scientific research.

About Lucid Therapeutics

At Lucid Therapeutics, we provide you with the best standard of care for your ketamine therapy and integration. Our goal is to help you experience the best possible results that enable you to move from feeling sucked into a place of agency and energy to live your desired life.


This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News at the speed of influence™. Reference URL for this press release is here.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.